1. The Mountain is You, by Wiest
2. All About Love, by Hooks
3. The Celestine Prophecy, by Redfield
4. How to Change Your Mind, by Pollan.
5. The Ketamine Papers, by Wolfson
6. Ketamine for Depression, Hyde
7. The Psychedelic Explorer’s Guide, Fadiman
8. Psychedelics and Psychotherapy, Papaspyrou, Mate
9. No Bad Parts, Schwartz
10. Wherever You Go, There You Are, Kabat-Zinn 8. The Untethered Soul, Singer 11. The Body Keeps the Score, Van Der Kolk
12. Psychedelic Integration, Aixala
Ketamine therapy is raising concerns about overdoses, addiction and predatory business practices
Ketamine in Chronic Pain: A Review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908414/
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10700627/
Ketamine: Mechanisms and Relevance to Treatment of Depression
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635017/
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
https://www.sciencedirect.com/science/article/abs/pii/S0022395622002400?via%3Dihub
Comprehensive Guide to Ketamine Therapy:
https://www.mayahealth.com/blog/a-comprehensive-guide-to-ketamine-therapy
How Does Ketamine Work Differently from Other Psychedelics? (Psychology Today):
https://www.psychologytoday.com/us/blog/the-lucid-mind/202105/how-does-ketamine-work-differently-other-psychedelics
Psychedelic Medicine 101: The curious case of ketamine:
https://newatlas.com/psychedelic-medicine-ketamine/54970/
Ketamine Clinics: Does a Physician’s Specialty Matter?:
https://harris-sliwoski.com/psychlawblog/ketamine-clinics-does-a-physicians-specialty-matter/
Everything You Need to Know About Using Ketamine:
https://www.vice.com/en/article/bjbdg8/how-to-take-ketamine-risks-side-effects-drug-test
Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression:
https://pubmed.ncbi.nlm.nih.gov/23683309/
Ketamine as an Emerging Treatment for Anxiety, Depression, Autism, and Other Conditions:
https://www.mayahealth.com/blog/ketamine-as-an-emerging-treatment-for-anxiety-depression-autism-and-other-conditions
Ethical Guidelines for Ketamine Clinicians and Commentary:
https://static1.squarespace.com/static/56afda3522482e15b61cd08a/t/602d5ac9eb1bd95076b8e533/1613585104325/ JPP-2021-01.pdf
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy:
https://www.tandfonline.com/doi/pdf/10.1080/02791072.2019.1587556
Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study by Davis, Mangini, Xi, 2021:
https://akjournals.com/view/journals/2054/5/2/article-p94.xml
I really like this podcast. Dr. Krystal is western medicine all the way. This is a great story about how ketamine came to be used in the field of mental health.
Dr. John Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. Dr. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizophrenia, and depression. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients.
Roland Griffiths, PhD did the seminal study on psychedelics and end-of-life care.
This was what got me interested in this work.
Roland Griffiths, PhD, is a Professor in the Departments of Psychiatry and Neurosciences at Johns Hopkins University, and founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research. His principal research focus in both clinical and preclinical laboratories has been on the behavioral and subjective effects of mood-altering drugs. His research has been largely supported by grants from the National Institute on Health, and he is author of over 400 scientific publications. He has been a consultant to the National Institutes of Health, the World Health Organization, and numerous pharmaceutical companies. Roland has conducted extensive research with sedative-hypnotics, caffeine, and novel mood-altering drugs.
This person is on the vanguard of psychedelic research. She’s studying critical period and psychedelics.
Dr. Gül Dölen is an associate professor of Neuroscience at the Johns Hopkins University School of Medicine and a pioneer and world leader of psychedelics research. Her laboratory has discovered a novel mechanism that could account for the broad range of therapeutic applications that psychedelics are currently being tested for. Her lab has discovered a novel critical period for social reward learning and shown that this critical period can be reopened with psychedelic drugs, such as MDMA, LSD, psilocybin, ketamine, and ibogaine. Building on this discovery, she has formulated the hypothesis that psychedelics may be the long sought “master key” for unlocking critical periods across the brain. To test this hypothesis, she has initiated a nationwide collaborative effort to determine whether psychedelics reopen critical periods for ocular dominance plasticity, bird song learning, anatomical plasticity in the barrel cortex, serotonergic neuronal regeneration, dendritic spinogenesis, and motor learning.
The godfather of ketamine in mental health since the 70s. His approach is different from Dr. Krystal’s efforts.
Phil Wolfson: Is Recreational Ketamine Therapeutic